Patents Assigned to Myelos Corporation
  • Publication number: 20120172305
    Abstract: This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the same activity as native IL-6 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage.
    Type: Application
    Filed: October 28, 2011
    Publication date: July 5, 2012
    Applicant: MYELOS CORPORATION
    Inventors: DAVID E. WRIGHT, D. ELLIOT PARKS
  • Publication number: 20110306558
    Abstract: Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons.
    Type: Application
    Filed: February 7, 2011
    Publication date: December 15, 2011
    Applicant: MYELOS CORPORATION
    Inventors: John S. O'BRIEN, Yasuo KISHIMOTO
  • Patent number: 8063016
    Abstract: This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO: 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the same activity as native IL-6 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: November 22, 2011
    Assignee: Myelos Corporation
    Inventors: David E. Wright, D. Elliot Parks
  • Publication number: 20110195908
    Abstract: Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons.
    Type: Application
    Filed: April 13, 2011
    Publication date: August 11, 2011
    Applicant: Myelos Corporation
    Inventors: John S. O'Brien, Yasuo Kishimoto
  • Publication number: 20110190213
    Abstract: The invention provides methods of treatment using retro-inverso peptides derived from interleukin-3 (IL-3) having between 12 and about 40 amino acids and including the sequence that is retro-inverso with respect to SEQ ID NO: 1. The peptides of the invention have the same activity as native IL-3 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage.
    Type: Application
    Filed: March 16, 2010
    Publication date: August 4, 2011
    Applicant: MYELOS CORPORATION
    Inventors: David E. WRIGHT, D. Elliot PARKS
  • Publication number: 20100286072
    Abstract: This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO: 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the same activity as native IL-6 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage.
    Type: Application
    Filed: March 31, 2010
    Publication date: November 11, 2010
    Applicant: MYELOS CORPORATION
    Inventors: David E. WRIGHT, D. Elliot PARKS
  • Publication number: 20100260734
    Abstract: A method for stimulating prosaposin receptor activity in a cell by transfecting the cell with a DNA or RNA molecule encoding prosaposin or a prosaposin receptor agonist. The DNA or RNA molecule is administered either in vivo or used to transfect neural cells or neural stem cells ex vivo followed by reintroduction of the cells into an individual.
    Type: Application
    Filed: April 15, 2010
    Publication date: October 14, 2010
    Applicant: MYELOS CORPORATION
    Inventors: John S. O'BRIEN, D. Elliot PARKS
  • Patent number: 7754688
    Abstract: This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO: 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the same activity as native IL-6 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: July 13, 2010
    Assignee: Myelos Corporation
    Inventors: David E. Wright, D. Elliott Parks
  • Patent number: 7754690
    Abstract: The invention provides methods of treatment using retro-inverso peptides derived from leukemia inhibitory factor (LIF) having between 18 and about 40 amino acids and including the sequence that is retro-inverso with respect to SEQ ID NO: 1. The peptides of the invention have the same activity as native LIF and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: July 13, 2010
    Assignee: Myelos Corporation
    Inventors: David E. Wright, D. Elliott Parks
  • Patent number: 7524818
    Abstract: Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons.
    Type: Grant
    Filed: June 18, 2003
    Date of Patent: April 28, 2009
    Assignee: Myelos Corporation
    Inventors: John S. O'Brien, Yasuo Kishimoto
  • Patent number: 7135461
    Abstract: Retro-inverso peptides derived from interleukin-6 (IL-6) having between 17 and about 40 amino acids and including the sequence shown in SEQ ID NO: 1. These peptides have the same activity as native IL-6 and also have neurotrophic activity. Because of the D-amino acid linkage in the peptides, they are less susceptible to proteolytic degradation in vivo.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: November 14, 2006
    Assignee: Myelos Corporation
    Inventors: David E. Wright, D. Elliott Parks
  • Patent number: 7115571
    Abstract: Retro-inverso peptides derived from interleukin-3 (IL-3) having between 12 and about 40 amino acids and including the sequence shown in SEQ ID NO: 1. These peptides have the same activity as native IL-3 and also have neurotrophic activity. Because of the D-amino acid linkage in the peptides, they are less susceptible to proteolytic degradation in vivo.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: October 3, 2006
    Assignee: Myelos Corporation
    Inventors: David E. Wright, D. Elliott Parks
  • Patent number: 7109168
    Abstract: Retro-inverso peptides derived from leukemia inhibitory factor (LIF) having between 18 and about 40 amino acids and including the sequence shown in SEQ ID NO: 1. These peptides have the same activity as native LIF and also have neurotrophic activity. Because of the D-amino acid linkage in the peptides, they are less susceptible to proteolytic degradation in vivo.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: September 19, 2006
    Assignee: Myelos Corporation
    Inventors: David E. Wright, D. Elliott Parks
  • Patent number: 6590074
    Abstract: Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons.
    Type: Grant
    Filed: November 26, 1996
    Date of Patent: July 8, 2003
    Assignee: Myelos Corporation
    Inventors: John S. O'Brien, Yasuo Kishimoto
  • Patent number: 6559124
    Abstract: Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons.
    Type: Grant
    Filed: May 12, 1998
    Date of Patent: May 6, 2003
    Assignee: Myelos Corporation
    Inventors: John S. O'Brien, Yasuo Kishimoto
  • Patent number: 6458357
    Abstract: Retro-inverso peptide analogs derived from the active neurotrophic region of saposin C. The saposin C-derived peptides (prosaptides) induce neurite outgrowth in vitro, prevent programmed cell death, induce myelination and have an analgesic effect. They are useful in the treatment of central and peripheral nervous system disorders and pain management. The retro-inverso peptides are significantly more resistant to metabolic degradation than the corresponding non-inverted peptides.
    Type: Grant
    Filed: September 3, 1998
    Date of Patent: October 1, 2002
    Assignee: Myelos Corporation
    Inventors: Michael T. White, John S. O'Brien, David E. Wright
  • Publication number: 20020077275
    Abstract: Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination exvivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons.
    Type: Application
    Filed: January 22, 2001
    Publication date: June 20, 2002
    Applicant: Myelos Corporation.
    Inventors: John S. O'Brien, Yasuo Kishimoto
  • Patent number: 5571787
    Abstract: Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons.
    Type: Grant
    Filed: July 30, 1993
    Date of Patent: November 5, 1996
    Assignee: Myelos Corporation
    Inventors: John S. O'Brien, Yasuo Kishimoto